EOLS FY 2023 Earnings — Evolus, Inc. Revenue & Financial Results | Market Cap Arena

EOLSEvolus, Inc.

$353M

FY 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$202M+36.0% YoY

Gross Profit

$141M69.5% margin

Operating Income

-$49M-24.4% margin

Net Income

-$62M-30.5% margin

EPS (Diluted)

$-1.08

Cash Flow

Operating Cash Flow

-$34M

Free Cash Flow

-$36M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$189M

Total Liabilities

$210M

Stockholders' Equity

-$21M

Cash & Equivalents

$63M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$202M	$149M	+36.0%
Gross Profit	$141M	$90M	+56.5%
Operating Income	-$49M	-$65M	+24.6%
Net Income	-$62M	-$74M	+17.1%